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ABSTRACT
Collecting representative sets of cancer microRNAs
(miRs) from the literature we show that their corres-
ponding families are enriched in sets of highly inter-
acting miR families. Targeting cancer genes on a
statistically significant level, such cancer miR
families strongly intervene with signaling pathways
that harbor numerous cancer genes. Clustering miR
family-specific profiles of pathway intervention, we
found that different miR families share similar inter-
action patterns. Resembling corresponding patterns
of cancer miRs families, such interaction patterns
may indicate a miR family’s potential role in
cancer. As we find that the number of targeted
cancer genes is a naı¨ve proxy for a cancer miR
family, we design a simple method to predict candi-
date miR families based on gene-specific inter-
action profiles. Assessing the impact of miR
families to distinguish between (non-)cancer
genes, we predict a set of 84 potential candidate
families, including 75% of initially collected cancer
miR families. Further confirming their relevance,
predicted cancer miR families are significantly
indicated in increasing, non-random numbers of
tumor types.
INTRODUCTION
MicroRNAs (miRs) are small non-coding ribonucleic
acids with mature transcripts of 18–25 nucleotides that
interact with their gene target coding messenger RNA
(mRNA). Such interactions cause mRNA degradation
and putatively inhibit translation by direct and imperfect
binding to the 30- and 50-untranslated regions (UTR).
Although they are powerful tuners of mRNA translation
themselves, miRs also exert control in combination
with other regulatory elements such as transcription
factors (1,2).
The elementary role of miRs in gene expression has
been indicated in tissue- and organ-speciﬁc development
(3) and the classiﬁcation of tumors (4,5). Over-expressed
miRs might diminish the expression levels of targeted
tumor suppressor genes, reﬂecting the functionality of an
oncomir. In turn, tumor suppressor miRs are known for
targeting genes with oncogenic properties and for being
either down regulated or deleted in tumor tissue, leading
to a higher expression rate of targeted oncogenes (6).
Recently, several miRs were identiﬁed as being involved
in various steps of the metastatic process (7), a different
group of cancer-related miRs that are known as
metastamiRs.
From a genomic perspective, clusters of miRs are fre-
quently located in common breakpoint regions and
genomic areas of ampliﬁcation and loss of heterozygosity
(8). For example, patients suffering from B-cell chronic
lymphocytic leukemia (CLL) often show down regulation
of miR-15a and miR-16-1. In addition, these miRs are
located at chromosome 13q14, a deleted genomic area in
more than 65% of patients with CLL (8). In general, such
genomic perturbations of miRs have been identiﬁed in the
expression regulation of tumor-associated genes in many
cancer types (6,9–11). Alternatively, genomically unper-
turbed miR clusters may be dysregulated by transcription
factors that govern their expression. For example, tran-
scription factor MYC shows disrupted expression regula-
tion in cancers and transactivates the miR-17-92 cluster.
Furthermore, dysregulation of MYC by chromosomal
translocation and juxtaposition to an immunoglobulin
enhancer causes Burkett’s lymphoma (12,13).
Collecting cancer-related miRs from the literature, we
used TargetScan (14) to group miRs into families accord-
ing to their corresponding seed sequences. We showed
that miR families containing cancer-related miRs gener-
ally tend to target many mRNAs. Although cancer miR
families were further enriched among families that
targeted many cancer genes, we statistically conﬁrmed
that cancer miR families indeed targeted cancer genes on
a statistically signiﬁcant level. Although cancer genes pre-
dominantly were highly connected in a web of protein
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interactions, cancer miR families reinforced their enrich-
ment among protein hubs, allowing broad access to sig-
naling pathways. Analyzing their impact on signaling
pathways, different miR families not only intervene in
similar sets of signaling pathways through targeting
cancer genes. We also observed that such interaction
patterns resembled corresponding targeting patterns of
other cancer miR families, potentially indicating a role
in cancer. As we found that the sole number of targeted
cancer genes alone reasonable classiﬁed a families involve-
ment in cancer, we designed a method to predict candidate
cancer miR families. Assuming that interaction patterns
differed between (non-)cancer genes, we found a set of
candidate cancer miR families that largely overlapped
with initially collected cancer miR families.
MATERIALS AND METHODS
Cancer miRs and -genes
We collected 35 oncomiRs, 32 metastamiRs (7,15–17) and
42 tumor suppressor miRs (16–21) from the literature.
Using family information from TargetScan (14), we
assigned oncomiRs to 19 miR families with identical
seed sequences, whereas we found 26 families containing
42 tumor suppressor miRs. Furthermore, 32 metastamiRs
corresponded to 23 miR families. We used data from
HMDD database, collecting experimental information
about the involvement of single miRs in more than 90
cancer types from the scientiﬁc literature (22). As for
cancer genes, we used 496 oncogenes and 876 tumor sup-
pressor genes from the CancerGenes database (23).
miR–mRNA interactions
We assembled 72 770 predicted, conserved interactions
between 153 miRNA families and 11 161 mRNAs, using
human-speciﬁc data from TargetScan (14). Speciﬁcally,
families were deﬁned as groups of miRs that had the
same seed sequence.
Human protein–protein interactions
and signaling pathways
As a representative set of human protein–protein inter-
actions, we pooled 73 869 interactions between 11 446
human proteins from Reactome (24), MINT (25) and
HPRD (26). As a comprehensive collection of human ca-
nonical signaling pathways, we used information about
184 signaling pathways from the PID database (27).
Enrichment
We grouped N miR families according to their number of
interactions where each group was represented by Nk
families with a certain number of targeted mRNAs, k.
Out of a set of Nc families with cancer miRs we calculated
the corresponding subset Nc,k in each group.
As a control, we collected a set of non-cancer miR
families, Nnc, that was larger than the set of families
with cancer miRs, Nnc



 > Nc



. Picking a random set of
non-cancer control families of equal size Nrnc, N
r
nc



 ¼ Nc



,
we deﬁned Ec,k ¼ Nc,kj j
Nr
nc,k




as the enrichment of families
with cancer miRs among families with k mRNA targets.
Using human protein interactions or signaling
pathways, we grouped proteins according to their corres-
ponding number k of interactions or involved pathways.
Analogously, we determined the set of proteins with a
feature i (e.g. being a cancer gene or targeted by a
cancer miR family) in each group, Ni,k. As a null
model, we randomly sampled protein sets of equal size
Nij j ¼ Nri



 and deﬁned the enrichment of proteins with
feature i in a set of Nk proteins as Ei,k ¼ Ni,kj j
Nr
i,k




.
Generally, we averaged E over 1000 randomizations.
Note, that E> 1 points to an enrichment and vice versa
(28), whereas the choice of a randomized control set of
equal size allows us to obtain a normalized enrichment
score, E c,if g,k ¼ 1 when k ¼ 1.
Random Forest algorithm
Random Forests is an ensemble learning method (29)
where classiﬁcation trees are constructed using N different
bootstrap samples of the data (‘bagging’). In addition,
random forests change how trees are constructed by
splitting each node, using the best among a subset of M
randomly chosen predictors (‘boosting’). New data are
predicted by aggregating the predictions of N trees.
We represented all interactions between m=11161
genes and n=153 targeting miR families as a binary
matrix and labeled each gene as (non-)cancer-related.
Randomly picking
ﬃﬃﬃﬃ
m
p
out of all m genes, we used
ﬃﬃﬃ
n
p
variables for the construction of each of 1000 trees.
Speciﬁcally, we ensured that the number of randomly
sampled (non-) cancer genes in each tree corresponded
to the priors of (non-)cancer classes.
A miR family’s i impact on the discrimination process
was measured by their corresponding normalized import-
ance deﬁned as Ii ¼ Iii, where Ii and i are the importance
and standard deviation of family i, respectively. Assessing
their statistical signiﬁcance, we permuted the targets of
each miR family by keeping their initial number of
targeted mRNAs constant. Subsequently, we calculated
randomized, normalized importance values of each miR
using the same parameters. Repeating the randomization
process 100 times, we constructed null distributions of
normalized importance scores for each miR. Fitting such
distributions with a Z test, we calculated P values and con-
sidered all miR families with a FDR< 0.01 (30).
RESULTS
Characteristics of cancer miR families
We collected a total of 72 miRs from the literature, con-
sisting of overlapping sets of 35 onco-, 42 tumorsup-
pressor- and 34 metastamiRs (16–21) (Supplementary
Table S1). Using TargetScan (14), we grouped miRs in
families that shared the same seed sequence. Assigning
such cancer-related miRs to such groups, we obtained a
total of 47 cancer miR families. On a more detailed level,
we obtained 19 families with oncomiRs, whereas we found
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26 families with tumor suppressor miRs and 23 miR
families with metastamiRs (Supplementary Table S1).
Notably, such families overlapped to a considerable
degree (inset, Figure 1A).
To identify mRNA targets of miRs, we used computa-
tional predictions of interactions from TargetScan (14),
assembling 72 770 interactions between 11 161 mRNAs
and 153 miR families. Such a set of interactions
included 40 of 47 cancer miR families that we collected
from the literature. As cancer genes are particularly placed
in groups of highly interacting proteins (31), we
hypothesized that highly interacting miR families may in-
creasingly harbor cancer miRs. In groups of miR families
that interacted with at least k mRNA targets, we
determined the corresponding number of families with
cancer miRs. As for a non-cancer control set, we
selected families that neither involved any literature-
curated cancer miRs nor were otherwise reported in a
cancer type. Using the HMDD database that collects lit-
erature about the involvement of single miRs in more than
90 tumor types (22), we carefully compiled a set of 51
non-cancer control families. Controlling for similar pre-
dicted miR target sites, we also demanded that such
control miR families show similar seed match conserva-
tion levels of their corresponding UTRs compared with
cancer miR families. As a conservation metric, we used
the number of orthologous UTR sequences from different
organisms that indicate conserved matches to the seed se-
quences of a given miR. Focusing on our sets of cancer
and control miR families, we observed similar distribu-
tions in Supplementary Figure S1, indicating similar con-
servation levels. In Figure 1A, we calculated the
enrichment of cancer miR families as a function of the
number of interactions between miRs of a family and
their corresponding mRNA targets. As our control set
of non-tumor miR families was larger than the sets of
cancer miR families, we selected random subsets of
equal size out of 51 non-cancer families. Subsequently,
we calculated enrichment as the ratio of the number of
families with cancer miRs and non-cancer families in
each group. Averaging over 1000 randomizations, we
observed that families with onco-, tumor suppressor and
Figure 1. Characteristics of cancer miR families. (A) From the literature, we collected cancer miRs that were involved in 43 miR families.
Considering onco-, tumor suppressor- and metastamiRs separately, we observed that their corresponding sets of miR families considerably
overlapped (inset). In the main ﬁgure, we grouped miR families in bins where each family had at least k target genes. Compared with a non-cancer
control set of families, we observed that families of onco-, tumor suppressor- and metastamiRs were enriched in groups of families that had an
increasing number of targets. (B) Analogously, we grouped miR families according to their corresponding number of targeted onco- and tumor
suppressor genes, respectively. Compared with a non-tumor control set of miR families, we observed that miR families involved in cancer tend to
interact with an elevated number of cancer genes. (C) P values of Fisher’s exact tests indicated that cancer miR families signiﬁcantly interacted with
cancer genes. (D) We determined the enrichment of cancer genes as a function of a gene’s number of interaction partners in a human protein
interaction network. Speciﬁcally, we grouped genes in bins where each gene was at least involved in k interactions. Although the enrichment of
cancer genes increased in groups of highly interacting proteins, we observed an enforcement of the initial signal, considering cancer genes that were
targeted by cancer miR families. In the inset, cancer-related genes were enriched in groups that appeared in an increasing number of pathways.
Similarly, we observed a reinforcement of the initial trend considering cancer genes that interacted with cancer miR families.
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metastamiRs were predominately enriched in groups of
highly interacting miR families (Figure 1A).
Expecting that cancer miRs exert their inﬂuence on the
expression of cancer genes through their interactions with
corresponding mRNAs, we collected 496 onco- and 876
tumor suppressor genes from the CancerGenes database
(23). Hypothesizing that cancer miR families may target
many different cancer genes, we determined the enrich-
ment of such families as a function of the number of
targeted onco- and tumor suppressor genes. Using our
cohort of non-cancer miR families as controls, we
observed increasing trends in Figure 1B, suggesting that
cancer miR families indeed tend to frequently target
cancer genes. Testing the signiﬁcance that cancer miR
families indeed prefer to target cancer genes, we applied
Fisher’s exact test, allowing us to ﬁnd a statistically sig-
niﬁcant tendency of families with onco-, tumor suppres-
sor- and metastamiRs to predominately interact with
onco- and tumor suppressor genes (Figure 1C).
As a corollary of these observations, we assumed that
the enrichment of cancer genes among protein hubs in
networks of interacting proteins may be reinforced by
cancer miR families. Assembling a network of 73 869
protein–protein interactions between 11 446 human
proteins (24–26), we grouped proteins in bins where each
protein had at least k interactions. Pooling all 1259 onco-
and tumor suppressor genes, we determined the number of
such cancer genes in each group. As a baseline, we con-
sidered the enrichment of cancer genes as a function of the
corresponding number of interaction partners by
randomly picking cancer genes (Figure 1D). Focusing on
all cancer genes that were targeted by cancer miR families,
we observed an enhancement of the initial enrichment
signals. As a consequence, we assumed that such a re-
inforcement signal may translate into an elevated involve-
ment in pathways, as highly connected proteins tend to
appear in an increasing number of pathways (32). Using
184 human signaling pathways from the PID database
(27), we grouped proteins in bins where each protein
participated in at least k pathways. Determining the
number of cancer genes in each group, we randomly
sampled sets of cancer genes, allowing us to ﬁnd a
strong enrichment signal in groups of genes that were
involved in an increasing number of pathways (inset,
Figure 1D). Focusing on cancer genes that were targeted
by cancer miR families, we found a reinforcement of the
initial trend.
Prediction of families involved in cancer
Providing a bigger picture, we mapped the relationships
between signaling pathways and miR families by counting
the number of cancer genes in each pathway that were
targeted by a given family. Applying ward clustering to
such family-speciﬁc proﬁles of pathway intervention
(Figure 2), we found a large cluster that signiﬁcantly
pooled a large fraction of cancer miR families and
indicated miR families with a strong involvement in sig-
naling pathways. For example, family miR-15ab/16/195/
424/497 that involved cancer miRs-15ab/16 showed
similar interaction patterns as co-clustered families
miR-27ab and miR-124/506. Such patterns may indicate
that the latter families harbored miRs with a role in cancer
as well. Assuming that similar interaction patterns of miR
families may allow us to ﬁnd families involved in cancer,
we used the number of targeted cancer genes to predict
cancer miR families. In a naı¨ve approach, we predicted a
miR family’s involvement in cancer as a function of their
number of targeted cancer genes. Using our set of
literature-curated families with cancer miRs, the area
under the receiver operating characteristic curve suggested
that increased targeting of cancer genes is indeed a clas-
sifying criterion for the determination of cancer miR
families (AUC=0.74).
As a corollary, gene-speciﬁc proﬁles of targeting miR
families may differ between (non-)cancer genes,
prompting us to hypothesize that families which signiﬁ-
cantly contributed to the discrimination process may be
potential families involved in cancer. Designing a simple
heuristic, (i) we represented interactions between each of
11 161 genes and all 153 miR families as a binary inter-
action proﬁle and labeled all cancer genes accordingly.
(ii) Applying the random forest algorithm (29), we
assessed each families’ impact by determining its
normalized importance, a measure that reﬂected the
mean decrease in accuracy when the given miR family
was unaccounted for in the discrimination process.
(iii) To assess the statistical signiﬁcance of normalized
importance values, we permuted miR family proﬁles and
calculated randomized, normalized importance scores.
Determining a P value for each family with a Z test, we
predicted 84 candidate cancer miR families with
FDR< 0.01 (30), including 30 of 40 (75%) literature
curated families with cancer miRs (Supplementary
Table S2).
Obtaining experimental evidence to assess the biological
relevance of candidate miR families, we mined data from
the HMDD database (22). In Figure 3B, we constructed a
bipartite matrix, indicating if at least one publication
reported the involvement of a given miR of a certain
family in a tumor type. Ward clustering such a matrix
allowed us to ﬁnd a cluster that accumulated the majority
of predicted and curated cancer miR families. For
example, we found mentioned families miR-27ab and
miR124/506 in this cluster, families that both were pre-
dicted as involved in cancer. Nested in this cluster, we
observed a small group of 23 miR families that appeared
in most cancer types. Speciﬁcally, we observed that family
miR-30abcdef/30abe-5p/384-5p was not only predicted to
be involved in cancer but also appeared in 20 different
cancer types. Furthermore, this family targeted
numerous cancer genes in signaling pathways (Figure 2),
indicating the family’s potential to play a role in cancer.
Generally, we observed that both literature collected
and predicted cancer miR families seemed to appear in a
higher number of tumor types than remaining families in
Figure 3B. We, therefore, hypothesized that the placement
of miR families in given tumor types was a non-random
process. Up to a certain year, we determined the average
number of tumor types where literature collected and can-
didate cancer miR families were reported in. To assess the
signiﬁcance that a set of miR families appeared in an
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observed average number of tumor types, we randomly
sampled sets of families of equal size out of all 153 target-
ing families. Subsequently, we calculated corresponding
average numbers of tumor types such families appeared
in and repeated these steps 105 times. After obtaining em-
pirical P values, we observed that literature-collected
cancer miR families appeared in a signiﬁcantly growing
average number of tumor types (upper panel,
Figure 3C). Analogously, we determined the signiﬁcance
of predicted families, suggesting a similarly increasing and
signiﬁcant trend of candidate families over the last couple
of years (lower panel, Figure 3C).
DISCUSSION
Collecting onco-, tumor suppressor- and metastamiRs
from the literature, we found that their corresponding
miR families were signiﬁcantly enriched in groups of
families with an elevated number of mRNA targets.
Such a result coincides with a well-known topological
characteristic of cancer genes that are mostly found in
groups of highly interacting human proteins. Focusing
on onco- and tumor suppressor genes, we signiﬁcantly
observed that cancer miR families preferably targeted an
increasing number of cancer genes, allowing us to
Figure 2. Involvement of miRs in signaling pathways. In the heatmap, we counted the number of cancer genes in a signaling pathway that were
targeted by a given family of miRs. Ward clustering such a matrix, we found a large cluster of families that strongly interacted with cancer genes in
signaling pathways and signiﬁcantly pooled a large fraction of cancer miR families. Cancer miRs collected from the literature were indicated in red in
their corresponding families.
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conclude that such families exerted their biological role
through perturbed ﬁne regulation of the expression of
cancer genes. As a consequence, enrichment of cancer
genes targeted by cancer miR families in groups of
highly interacting proteins was indeed enhanced. Such
an observation suggests that the interactions between
cancer miRs and genes add another layer to the discussion
of a genes topological role in cancer. Although cancer
genes alone predominately are hubs, their centrality in a
cellular network is further emphasized by a small group of
highly connected cancer miR families that modulate the
expression of the underlying genes.
Notably, we determined enrichment compared with a
non-tumor control set of miR families with no involve-
ment in cancer. Furthermore, such a control set also has
to address other biases. Speciﬁcally, conserved miRs are
more widely studied and therefore may have a higher
chance to be involved in cancers. Conversely, non-tumor
involved miRs may be non-conserved and may be pre-
dicted to interact with a low number of targets. To
control for such a bias, we demanded that families in
our non-tumor control set were involved in predicted
conserved interactions between miRs and mRNAs.
miR families also secure a strong inﬂuence in signaling
pathways through targeting cancer genes. Speciﬁcally, we
observed that other miRs may resemble pathway inter-
action patterns of cancer miRs, suggesting that such
patterns indicate novel cancer miR candidates. Resembling
interaction patterns may arise from similar seed sequences
of single miRs, leading to similar predicted mRNA targets.
However, we grouped miRs in families of identical seed
sequences, largely offsetting such effects. As a conse-
quence, we observed that families miR-27abc, 124/506,
181abcd/4262 and 200bc/426 shared similar pathway
interaction patterns in Figure 2, whereas their seed se-
quences differed strongly (miR-27abc: UCACAGU,
Figure 3. Prediction of candidate miR families involved in cancer. (A) In a naı¨ve approach, we used the number of targeted cancer genes to detect
miR families with cancer miRs. In the corresponding receiver operating characteristic curve, we observed a considerable AUC=0.74, indicating the
power of this simple classiﬁer. (B) In a binary matrix, we indicated miR families that were reported in a certain tumor type. Applying ward
clustering, we found a pronounced cluster that largely pooled candidate and curated cancer miR families. Furthermore, such families appeared in
high numbers of different tumor types. (C) Up to a certain year, we determined the average number of tumor types where predicted and curated
cancer miR families were reported in. The signiﬁcance of observed trends over the last years was conﬁrmed by randomly sampling sets of cancer miR
families. Analogously, candidate cancer miR families gained considerable signiﬁcance to appear in different tumor types over the last years, strongly
indicating that candidates may indeed play a potential role in cancer.
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miR-124/506: AAGGCAC, miR-181abcd/4262: ACAUU
CA and miR-200bc/429: AAUACUG).
On the simplest level, the number of targeted cancer
genes indeed is a reasonable classiﬁer to call a cancer
miR family. However, the prediction of potential candi-
date cancer miRs would necessitate the determination of
an optimized threshold in a supervised way by accounting
for already known cancer miR families. Furthermore,
such a naı¨ve approach considers miR families as being
independent from each other, therefore ignoring any com-
posite effects between families. Considering whole
gene-speciﬁc interaction proﬁles, we proposed a simple,
unsupervised method, enabling us to predict potential
cancer miR families. In particular, our previous observa-
tions prompted us to assume that miR interaction proﬁles
of cancer and non-cancer genes considerably differ,
allowing us to identify a subset of miR families that
distinguishes between (non-)cancer genes. As a proof of
concept, we notably found that the predicted and litera-
ture collected set largely overlapped, whereas candidate
cancer miR families appeared in a non-random, growing
number of different tumor types.
Although we do not account for any expression or
genomic perturbation data, we solely introduced disease-
speciﬁc information by choosing disease genes. Assuming
that miR interaction proﬁles of (non-)disease genes may
generally differ our method may be applicable to ﬁnd
families that play a role in other diseases as well.
Although miR families collected from the literature are
on average indicated in more cancer types, such an obser-
vation is putatively caused by researchers bias, as
well-studied miRs are usually considered ﬁrst as experi-
mental leads. However, the increasing number of tumor
types candidate cancer miR families are indicated in
suggest that predicted families already gained relevance
as serious candidates.
As we grouped miRs into families according to their
seed sequences, many predicted and literature-curated
families can be quite large, suggesting that rather a
subset of miRs contribute to cancer than a family of
miRs as a whole. Therefore, miR families should be con-
sidered as groups that potentially harbor single miRs with
a role in cancer. As such, predicted families may well serve
as potential leads to ﬁnd single cancer miRs and may sig-
niﬁcantly contribute to the determination of diagnostic
miR signatures and therapeutic targets in different
tumor types.
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